Straits Times Index
3,280.10 -7.65 (-0.23%) Nikkei
37,934.76 +306.28 (+0.81%) Hang Seng
17,651.15 +366.61 (+2.12%) FTSE 100
8,117.30 +38.44 (+0.48%) Bitcoin USD
64,180.15 +457.99 (+0.72%) CMC Crypto 200
1,383.80 -12.74 (-0.91%)
Bio-Techne Corp (TE1.MU)
| Previous close | 58.50 |
| Open | 59.50 |
| Bid | 58.00 x N/A |
| Ask | 59.00 x N/A |
| Day's range | 59.50 - 59.50 |
| 52-week range | 50.00 - 80.00 |
| Volume | |
| Avg. volume | 0 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | 01 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
PR NewswireBIO-TECHNE AND NOVOMOL-Dx ANNOUNCE POINT-OF-CARE OCULAR BIOMARKER ASSAY
Bio-Techne Corporation (NASDAQ: TECH) and Novomol-Dx, a molecular diagnostics company, are pleased to announce the development of Bio-Marker Pathfinder (BMP), a first of its kind ocular biomarker kit, as a point-of-care application. Novomol-Dx is a molecular diagnostics company focused on commercializing tests for the diagnosis and treatment of ophthalmic diseases utilizing biomarkers discovered over the last decade at Narayana Nethralaya Foundation, in association with Grow Laboratories & Naray
- PR Newswire
BIO-TECHNE FILES PATENT INFRINGEMENT LAWSUIT AGAINST MOLECULAR INSTRUMENTS
Bio-Techne Corporation (NASDAQ: TECH), a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities, today announced that it has taken legal action in the Unified Patent Court in Europe to halt the infringement of its patented RNAscope® ISH technology by Molecular Instruments, Inc.
- PR Newswire
BIO-TECHNE TO HOST CONFERENCE CALL ON MAY 1, 2024, TO ANNOUNCE THIRD QUARTER FISCAL 2024 FINANCIAL RESULTS
Bio-Techne Corporation (NASDAQ: TECH) today announced that management will host a conference call and webcast on Wednesday, May 1, 2024, at 8:00 a.m. CDT to review third quarter fiscal 2024 financial results.
